Heparin oligosaccharides as potential therapeutic agents in senile dementia

Current Pharmaceutical Design

Volumn 13, Issue 15, 2007, Pages 1607-1616

  Ma, Qing ^a,c   Cornelli, Umberto ^a   Hanin, Israel ^a   Jeske, Walter P ^a   Linhardt, Robert J ^b   Walenga, Jeanine M ^a   Fareed, Jawed ^a   Lee, John M ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Fibroblast growth factors; Non anticoagulant actions; Pentasaccharide sequence; Serine protease inhibitors; Tissue factor pathway inhibitor

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; ANTIOXIDANT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 12A; CERTOPARIN; CHOLINESTERASE INHIBITOR; ENOXAPARIN; ESTROGEN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; FONDAPARINUX; GLYCOSAMINOGLYCAN POLYSULFATE; HEPARAN SULFATE; HEPARIN; HEPARIN DERIVATIVE; HOMOTAURINE; LOW MOLECULAR WEIGHT HEPARIN; NERVE GROWTH FACTOR; OLIGOSACCHARIDE; PENTASACCHARIDE; PRESENILIN 1; PRESENILIN 2; PROTEOGLYCAN; SANORG 32701; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TRYPSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CLINICAL TRIAL; COST OF ILLNESS; DEEP VEIN THROMBOSIS; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; HEALTH CARE COST; HUMAN; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SENILE DEMENTIA; SENILE PLAQUE; STRUCTURE ACTIVITY RELATION;

ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS; FIBROBLAST GROWTH FACTOR 2; HEPARIN; HUMANS; LIPOPROTEINS; NEUROPROTECTIVE AGENTS; OLIGOSACCHARIDES; RISK FACTORS; SERINE PROTEINASE INHIBITORS;

EID: 34249848228     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780765918     Document Type: Review

References (110)

1. McLean J. The discovery of heparin. Circulation 1959; 19: 75.
2. Best CH. Preparation of heparin and its use in the first clinical cases. Circulation 1959; 19: 79.
3. Fareed J, Hoppensteadt DA. Heparins in the new millennium: will unfractionated heparin survive? Epilogue. Semin Thromb Hemost 2000; 26(Suppl 1): 87.
4. Rosenberg RD, Lam L. Correlation between structure and function of heparin. Proc Natl Acad Sci USA 1979; 76: 1218.
5. Choay J. Chemically synthesized heparin-derived oligosaccharides. Ann N Y Acad Sci 1989; 556: 61.
6. Fareed J, Hoppensteadt D, Jeske W, Clarizio R, Walenga JM. Low molecular weight heparins: are they different? Can J Cardiol 1998; 14(Suppl E): 28E.
7. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119(Suppl 1): 64S.
8. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688.
9. Fareed J. Heparin, its fractions, fragments and derivatives: some newer perspectives. Semin Thromb Hemost 1985; 11: 1.
10. Walenga JM, Jeske WP, Bara L, Samama MM, Fareed J. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 1997; 86: 1.
11. Ma Q, Dudas B, Daud A, Iqbal O, Hoppensteadt D, Jeske W, et al. Molecular and biochemical profiling of a heparin-derived oligosaccharide C3. Thromb Res 2002; 105: 303.
12. Cornelli U. The therapeutic approach to Alzheimer's disease. In: Casu B, Non-anticoagulant action of glycosaminoglycans. New York, Plenum Press 1996; 249-79.
13. McGeer PL, McGeer EG. Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 2001; 22: 799.
14. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993; 82: 3253.
15. Tyrrell DJ, Horne AP, Holme KR, Preuss JM, Page CP. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999; 46: 151.
16. Esmon, CT. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med 2002; 196: 561.
17. Ekre HP. Inhibition of human and Guinea pig complement by heparin fractions differing in affinity for antithrombin III or in average molecular weight. Int J Immunopharmacol 1985; 7: 271.
18. Ekre HP, Fjellner B, Hagermark O. Inhibition of complement dependent experimental inflammation in human skin by different heparin fractions. Int J Immunopharmacol 1986; 8: 277.
19. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins: implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998; 101: 877.
20. Ahmed T, Ungo J, Zhou M, Campo C. Inhibition of allergic late airway responses by inhaled heparin-derived oligosaccharides. J Appl Physiol 2000; 88: 1721.
21. Stutzmann JM, Mary V, Wahl F, Grosjean-Piot O, Uzan A, Pratt J. Neuroprotective profile of enoxaparin, a low molecular weight heparin, in in vivo models of cerebral ischemia or traumatic brain injury in rats: a review. CNS Drug Rev 2002; 8: 1.
22. Yanaka K, Nose T. Heparin ameliorates brain injury by inhibiting leukocyte accumulation. Stroke 1996; 27: 2146.
23. Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I. A heparin-binding angiogenic protein basic fibroblast growth factor is stored within basement membrane. Am J Pathol 1988; 130: 393.
24. Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 1996; 84: 911.
25. Haynes LW. Fibroblast (heparin-binding) growing factors in neuronal development and repair. Mol Neurobiol 1988; 2: 263.
26. Ortega S, Ittmann M, Tsang SH, Ehrlich M, Basilico C. Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. Proc Natl Acad Sci USA 1998; 95: 5672.
27. Slack JM, Darlington, BG Heath JK, Godsave SF. Mesoderm induction in early Xenopus embryos by heparin-binding growth factors. Nature 1987; 326: 197.
28. Mufson EJ, Kroin JS, Sendera TJ, Sobreviela T. Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog Neurobiol 1999; 57: 451.
29. Miao HQ, Ornitz DM, Aingorn E, Ben-Sasson SA, Vlodavsky I. Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound. J Clin Invest 1997; 99: 1565.
30. Ornitz DM, Yayon A, Flanagan JG, Svahn CM, Levi E, Leder P. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol 1992; 12: 240.
31. Vlodavsky I, Ishai-Michaeli R, Mohsen M, Bar-Shavit R, Catane R, Ekre HP, et al. Modulation of neovascularization and metastasis by species of heparin. Adv Exp Med Biol 1992; 313: 317.
32. Rusnati M, Presta M. Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans: biological implications in neovascularization. Int J Clin Lab Res 1996; 26: 15.
33. Schlessinger J, Lax I, Lemmon M. Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors? Cell 1995; 83: 357.
34. D'Amore PA. Heparin-endothelial cell interactions. Haemostasis 1990; 20(Suppl 1): 159.
35. Taniguchi T, Toi M, Tominaga T. Rapid induction of hepatocyte growth factor by heparin. Lancet 1994; 344: 470.
36. Yamazaki H, Oi H, Matsushita M, Inoue T, Tang JT, Nose T, et al. Heparin induces rapid and remarkable elevation of hepatocyte growth factor/scatter factor during trans-arterial embolization of renal cell carcinoma. Anticancer Res 1997; 17: 1435.
37. Conrad HE. Heparin-binding proteins. San Diego, Academic Press, 1998.
38. Barzu T, Lormeau JC, Petitou M, Michelson S, Choay J. Heparinderived oligosaccharides: affinity for acidic fibroblast growth factor and effect on its growth-promoting activity for human endothelial cells. J Cell Physiol 1989; 140: 538.
39. Ornitz DM, Herr AB, Nilsson M, Westman J, Svahn CM, Waksman G. FGF binding and FGF receptor activation by synthetic heparan-derived di- and trisaccharides. Science 1995; 268: 432.
40. Lindahl B, Westling C, Gimenez-Gallego G, Lindahl U, Salmivirta M. Common binding sites for beta-amyloid fibrils and fibroblast growth factor-2 in heparan sulfate from human cerebral cortex. J Biol Chem 1999; 274: 30631.
41. Rabins PV. Developing treatment guidelines for Alzheimer's disease and other dementias. J Clin Psychiatry 1998; 59(Suppl 11): 17.
42. Meek PD, McKeithan K, Schumock GT. Economic considerations in Alzheimer's disease. Pharmacotherapy 1998; 18: 68.
43. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120: 885.
44. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987; 325: 733.
45. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704.
46. Iqbal K, Grundke-Iqbal I. Ubiquitination and abnormal phosphorylation of paired helical filaments in Alzheimer's disease. Mol Neurobiol 1991; 5: 399.
47. Mayeux R, Sano M. Treatment of Alzheimer's disease. N Engl J Med 1999; 341: 1670.
48. Fisher A, Brandeis R, Haring R, Eshhar N, Heldman E, Karton Y, et al. Novel M1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: an unifying hypothesis. J Physiol Paris 1998; 92: 337.
49. Yamada K, Nitta A, Hasegawa T, Fuji K, Hiramatsu M, Kameyama T, et al. Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease. Behav Brain Res 1997; 83: 117.
50. Simpkins JW, Green PS, Gridley KE, Singh M, de Fiebre NC, Rajakumar G. Role of estrogen replacement therapy in memory enhancement and the prevention of neuronal loss associated with Alzheimer's disease. Am J Med 1997; 103: 19S.
51. Broe GA, Grayson DA, Creasey HM, Waite LM, Casey BJ, Bennett HP, et al. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol 2000; 57: 1586.
52. Prasad KN, Cole WC, Hovland AR, Prasad KC, Nahreini P, Kumar B, et al. Multiple antioxidants in the prevention and treatment of neurodegenerative disease: analysis of biologic rationale. Curr Opin Neurol 1999; 12: 761.
53. Howlett DR, Jennings KH, Lee DC, Clark MS, Brown F, Wetzel R, et al. Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration 1995; 4: 23.
54. Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG, Szarek WA. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1995; 1: 143.
55. Snow AD, Kinsella MG, Parks E, Sekiguchi RT, Miller JD, Kimata K, et al. Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease. Arch Biochem Biophys 1995; 320: 84.
56. Snow AD, Lara S, Nochlin D, Wight TN. Cationic dyes reveal proteoglycans structurally integrated within the characteristic lesions of Alzheimer's disease. Acta Neuropathol 1989; 78: 113.
57. Buee L, Ding W, Anderson JP, Narindrasorasak S, Kisilevsky R, Boyle NJ, et al. Binding of vascular heparan sulfate proteoglycan to Alzheimer's amyloid precursor protein is mediated in part by the n-terminal region of A4 peptide. Brain Res 1993; 627: 199.
58. Buee L, Ding W, Delacourte A, Fillit H. Binding of secreted human neuroblastoma proteoglycans to the Alzheimer's amyloid A4 peptide. Brain Res 1993; 601: 154.
59. Gupta-Bansal R, Frederickson RC, Brunden KR. Proteoglycan-mediated inhibition of a beta proteolysis: a potential cause of senile plaque accumulation. J Biol Chem 1995; 10: 18666.
60. Snow AD, Sekiguchi R, Nochlin D, Fraser P, Kimata K, Mizutani A, et al. An important role of heparan sulfate proteoglycan (perlecan) in a model system for the deposition and persistence of fibrillar a beta-amyloid in rat brain. Neuron 1994; 12: 219.
61. Kisilevsky R, Szarek WA, Ancsin J, Vohra R, Li Z, Marone S. Novel glycosaminoglycan precursors as antiamyloid agents: Part IV. J Mol Neurosci 2004; 24: 167.
62. Patey SJ, Yates EA, Turnbull JE. Novel heparan sulphate analogues: inhibition of beta-secretase cleavage of amyloid precursor protein. Biochem Soc Trans 2005; 33: 1116.
63. Scholefield Z, Yates EA, Wayne G, Amour A, McDowell W, Turnbull JE. Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's beta-secretase. J Cell Biol 2003; 163: 97.
64. Buee L, Hof PR, Delacourte A. Brain microvascular changes in Alzheimer's disease and other dementias. Ann N Y Acad Sci 1997; 826: 7.
65. Breteler MM. Risk factors for vascular disease and dementia. J Neural Transm 1998; 105: 773.
66. Breteler MM. Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann N Y Acad Sci 2000; 903: 457.
67. de la Torre JC. Vascular basis of Alzheimer's pathogenesis. Ann N Y Acad Sci 2002; 977: 196.
68. Khan AR, James MN. Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Protein Sci 1998; 7: 815.
69. Barrett AJ. The many forms and functions of cellular proteinases. Fed Proc 1980; 39: 9.
70. Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PG, et al. The Serpins are an expanding superfamily of structurally similar but functionally diverse proteins: evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001; 276: 33293.
71. Potempa J, Korzus E, Travis J. The Serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 1994; 269: 15957.
72. Janciauskiene S, Sun YX, Wright HT. Interactions of A beta with endogenous anti-inflammatory agents: a basis for chronic neuroinflammation in Alzheimer's disease. Neurobiol Dis 2002; 10: 187.
73. Highsmith RF, Rosenberg RD. The inhibition of human plasmin by human antithrombin-heparin cofactor. J Biol Chem 1974; 249: 4335.
74. Kalaria RN, Golde T, Kroon SN, Perry G. Serine protease inhibitor antithrombin III and its messenger RNA in the pathogenesis of Alzheimer's disease. Am J Pathol 1993; 143: 886.
75. Hollister RD, Kisiel W, Hyman BT. Immunohistochemical localization of tissue factor pathway inhibitor-1 (TFPI-1), a Kunitz proteinase inhibitor in Alzheimer's disease. Brain Res 1996; 728: 13.
76. Lomas DA, Carrell RW. Serpinopathies and the conformational dementias. Nat Rev Genet 2002; 3: 759.
77. Carrell RW, Lomas DA. Alpha1-antitrypsin deficiency - A model for conformational diseases. N Engl J Med 2002; 346: 45.
78. Westrick RJ, Bodary PF, Xu Z, Shen YC, Broze GJ, Eitzman DT. Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation 2001; 103: 3044.
79. Santini V. A general practice trial of Ateroid 200 in 8,776 patients with chronic senile cerebral insufficiency. Mod Probl Pharmacopsychiatry 1989; 23: 95.
80. Lorens SA, Guschwan M, Hata N, van de Kar LD, Walenga JM, Fareed J. Behavioral, endocrine, and neurochemical effects of sulfomucopolysaccharide treatment in the aged Fischer 344 male rat. Sem Thromb Hemost 1991; 17: S164.
81. Conti L, Placidi GF, Cassano GB. Ateroid in the treatment of dementia: results of a clinical trial Ateroid in the clinical treatment of multi-infarct dementia a general practice trial of Ateroid 200 in 8,776 patients with chronic senile cerebral insufficiency. Mod Probl Pharmacopsychiatry 1989; 23: 76.
82. Passeri M, Cucinotta D. Ateroid in the clinical treatment of multi-infarct dementia. Mod Probl Pharmacopsychiatry 1989; 23: 85.
83. Walzer M, Lorens S, Hejna M, Fareed J, Hanin I, Cornelli U, et al. Low molecular weight glycosaminoglycan blockade of beta-amyloid induced neuropathology. Eur J Pharmacol 2002; 445: 211.
84. Dudas B, Cornelli U, Lee JM, Hejna MJ, Walzer M, Lorens SA, et al. Oral and subcutaneous administration of the glycosaminoglycan C3 attenuates Abeta(25-35)-induced abnormal tau protein immunoreactivity in rat brain. Neurobiol Aging 2002; 23: 97.
85. Snow AD, Wight TN. Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Neurobiol Aging 1989; 10: 481.
86. Leveugle B, Ding W, Laurence F, Dehouck MP, Scanameo A, Cecchelli R, et al. Heparin oligosaccharides that pass the blood-brain barrier inhibit beta-amyloid precursor protein secretion and heparin binding to beta-amyloid peptide. J Neurochem 1998;70: 736.
87. Ma Q, Dudas B, Hejna M, Cornelli U, Lee JM, Lorens S, et al. The blood-brain barrier accessibility of heparin-derived oligosaccharides C3. Thromb Res 2002; 105: 447.
88. Ma Q, Schultz C, Neville B, Jeske W, Hoppensteadt D, Cornelli U, et al. Pharmacodynamics and pharmacokinetics of C3, a heparin-derived oligosaccharide mixture, in non-human primates. Thromb Res 2003; 112: 249.
89. Bergamaschini L, Donarini C, Rossi E, De Luigi A, Vergani C, De Simoni MG. Heparin attenuates cytotoxic and inflammatory activity of Alzheimer amyloid-beta in vitro. Neurobiol Aging 2002; 23: 531.
90. Farooqui AA, Litsky ML, Farooqui T, Horrocks LA. Inhibitors of intracellular phospholipase A2 activity: their neurochemical effects and therapeutical importance for neurological disorders. Brain Res Bull 1999; 49: 139.
91. Smith MA, Kalaria RN, Perry G. Alpha 1-trypsin immunoreactivity in Alzheimer disease. Biochem Biophys Res Commun 1993; 193: 579.
92. Ciallella JR, Figueiredo H, Smith-Swintosky V, McGillis JP. Thrombin induces surface and intracellular secretion of amyloid precursor protein from human endothelial cells. Thromb Haemost 1999; 81: 630.
93. Haas C, Aldudo J, Cazorla P, Bullido MJ, de Miguel C, Vazquez J, et al. Proteolysis of Alzheimer's disease beta-amyloid precursor protein by factor Xa. Biochim Biophys Acta 1997; 1343: 85.
94. Saporito-Irwin SM, Van Nostrand WE. Coagulation factor XIa cleaves the RHDS sequence and abolishes the cell adhesive properties of the amyloid beta-protein. J Biol Chem 1995; 270: 26265.
95. Yasuhara O, Walker DG, McGeer PL. Hageman factor and its binding sites are present in senile plaques of Alzheimer's disease. Brain Res 1994; 654: 234.
96. Shimizu-Okabe C, Yousef GM, Diamandis EP, Yoshida S, Shiosaka S, Fahnestock M. Expression of the kallikrein gene family in normal and Alzheimer's disease brain. Neuroreport 2001; 12: 2747.
97. Ledesma MD, Da Silva JS, Crassaerts K, Delacourte A, De Strooper B, Dotti CG. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep 2000; 1: 530.
98. Rebeck GW, Harr SD, Strickland DK, Hyman BT. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-density-lipoprotein receptor-related protein. Ann Neurol 1995; 37: 211.
99. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383.
100. Abraham CR, Selkoe DJ, Potter H. Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 1988; 52: 487.
101. Gollin PA, Kalaria RN, Eikelenboom P, Rozemuller A, Perry G. Alpha 1-antitrypsin and alpha 1-antichymotrypsin are in the lesions of Alzheimer's disease. Neuroreport 1992; 3: 201.
102. Akiyama H, Ikeda K, Kondo H, Kato M, McGeer PL. Microglia express the type 2 plasminogen activator inhibitor in the brain of control subjects and patients with Alzheimer's disease. Neurosci Lett 1993; 164: 233.
103. Turgeon VL, Houenou LJ. The role of thrombin-like (serine) proteases in the development, plasticity and pathology of the nervous system. Brain Res Brain Res Rev 1997; 25: 85.
104. Cacabelos R. Pharmacogenomics for t he treatment of dementia. Ann Med 2002; 34: 357.
105. Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M, et al. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 2007; 28(4): 537-47.
106. Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, et al. A Phase II study targeting amyloid-beta with 3APS in mildto-moderate Alzheimer disease. Neurology 2006; 67: 1757.
107. Aisen PS, Gauthier S, Briand R, Saumier D, Laurin J, Garceau D. Tramiprosate (Alzhemed™): a potential treatment for Alzheimer's disease. Presented at 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, Geneva, Switzerland, April 19-22, 2006.
108. D'Andrea MR, Nagele RG. Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons. Curr Pharm Des 2006; 12(6): 677-84.
109. Morelle W, Michalski JC. Glycomics and mass spectrometry. Curr Pharm Des 2005; 11(20): 2615-45.
110. Rusnati M, Oreste P, Zoppetti G, Presta M. Biotechnological engineering of heparin/heparan sulphate: a novel area of multi-target drug discovery. Curr Pharm Des 2005; 11(19): 2489-99.